C1 Esterase Inhibitor (Ruconest)

Ruconest is covered only for the FDA‑approved use — treatment of acute attacks of hereditary angioedema (HAE) due to C1‑INH deficiency (type I or II); other indications are excluded. Initial (and 12‑month) authorization requires baseline labs showing functional C1‑INH <50% and low serum C4, prescription by or consultation with an allergist/immunologist or HAE specialist, weight‑based dosing (50 IU/kg IV, max 4,200 IU, ≤2 doses/day), and reauthorization requires prior Ruconest use with documented favorable clinical response.

"Ruconest is indicated for the treatment of acute attacks of Hereditary Angioedema (HAE)."

Sign up to see full coverage criteria, indications, and limitations.